(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Chevron Says Damage at Wheatstone LNG Will Hamper Restart - 2Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 3Iran begins cloud seeding to induce rain amid historic drought
- 4A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- 5Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- Deadly attack on kindergarten reported in Sudan
- The many ways that baking is winter therapy. With a delicious ending
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
